Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2025

BackgroundIndividuals diagnosed with type 2 diabetes mellitus (T2DM) commonly exhibit elevated lipid levels and an increased body mass index (BMI). The impact of BMI on the efficacy of statins in reducing lipid levels among diabetic patients remains uncertain.

Diabetes 52

Diabetes BMI Obesity Outpatient 52

Science Daily - Heart Disease

JANUARY 17, 2024

Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.

Blood Pressure 125

Blood Pressure Obesity Risk Factors Diabetes 125

Cardiometabolic Health Congress

FEBRUARY 10, 2025

Obesity is a complex, chronic condition that significantly impacts cardiometabolic health and overall well-being. For example, the Diabetes Prevention Program (DPP) showed that participants who achieved exercise goals reduced their diabetes risk , even if they didnt meet weight-loss targets.

Obesity 52

Obesity Diet Exercise Diabetes 52

Science Daily - Heart Disease

SEPTEMBER 13, 2024

Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.

Diet 136

Diet Diabetes Cardiovascular Disease Obesity 136

HCPLive

FEBRUARY 5, 2024

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Blood Pressure 116

Blood Pressure Obesity Diabetes 116

Med Page Today

JANUARY 14, 2025

(MedPage Today) -- Medical experts from around the globe proposed a more nuanced approach to diagnosing obesity that does not rely exclusively on body mass index (BMI) alone. Writing in The Lancet Diabetes & Endocrinology, the global commission.

Obesity 100

Obesity BMI Diabetes 100

Cardiovascular Diabetology

FEBRUARY 11, 2024

Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.

Heart Failure 111

Heart Failure Diabetes Obesity 111

Cardiometabolic Health Congress

JANUARY 3, 2024

In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

Med Page Today

OCTOBER 29, 2024

(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.

Diabetes 100

Diabetes Kidney Disease Obesity 100

HCPLive

JUNE 23, 2024

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

Obesity 83

Obesity Diabetes 83

Med Page Today

MAY 11, 2024

(MedPage Today) -- NEW ORLEANS -- A "culturally sensitive" exercise intervention led to weight loss and other benefits in African-American women with obesity at risk for diabetes, researchers reported. The program tested in the ongoing, single.

Obesity 88

Obesity Exercise Diabetes Research 88

HCPLive

DECEMBER 22, 2024

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

Diabetes 116

Diabetes Obesity 116

HCPLive

JANUARY 3, 2025

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

Obesity 111

Obesity Diabetes 111

HCPLive

DECEMBER 19, 2023

Weight cycling could lead to a relative loss of fat-free mass in people living with overweight and obesity at high risk of type 2 diabetes.

Diabetes 106

Diabetes Obesity 106

Medical Xpress - Cardiology

JANUARY 17, 2024

Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published in the Journal of the American Heart Association.

Blood Pressure 92

Blood Pressure Obesity Diabetes Risk Factors 92

HCPLive

JANUARY 21, 2025

of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis. Approximately 2.0%

Obesity 72

Obesity Diabetes 72

Cardiovascular Diabetology

SEPTEMBER 11, 2024

Cardiovascular disease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.

Obesity 130

Obesity Risk Factors Cardiovascular Disease Diabetes 130

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

Science Daily - Heart Disease

SEPTEMBER 23, 2024

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.

Medicare 131

Medicare Obesity Cardiovascular Disease Diabetes 131

Frontiers in Cardiovascular Medicine

APRIL 24, 2025

GLP-1 RAs have been used for diabetes and found to improve CV outcomes in diabetic and nondiabetic patients. They are authorized for treating obesity. IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits.

Blood Pressure 52

Blood Pressure Diabetes Obesity Risk Factors 52

Med Page Today

DECEMBER 4, 2024

(MedPage Today) -- In part one of this three-part Instagram Live discussion, MedPage Today editor-in-chief Jeremy Faust, MD, talks about how GLP-1 receptor agonists are transforming diabetes and obesity care in a discussion with Karl Nadolsky.

Obesity 52

Obesity Diabetes 52

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 80

Preserved Ejection Fraction Diabetes Heart Failure Obesity 80

Med Page Today

JUNE 7, 2024

(MedPage Today) -- For people with obesity and diabetes, bariatric metabolic surgery was associated with a greater reduction in mortality compared with first-generation GLP-1 receptor agonists if the individuals had their diabetes for a decade.

Obesity 111

Obesity Diabetes 111

Becker's Hospital Review - Cardiology

AUGUST 27, 2024

22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.

Pharmacology 113

Pharmacology Obesity Diabetes 113

American Heart News - Heart News

FEBRUARY 18, 2025

adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidney disease, type 2 diabetes and obesity.[1] DALLAS, Feb. 18, 2025 About 90% of U.S. 1] This cluster of chronic health conditions is called.

Kidney Disease 116

Kidney Disease Obesity Heart Disease Diabetes 116

American College of Cardiology

JANUARY 8, 2024

Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.

Obesity 70

Obesity Atrial Fibrillation Heart Failure Risk Factors 70

Medical Xpress - Cardiology

APRIL 7, 2025

The five classic risk factors for cardiovascular disease are well knownsmoking, high blood pressure, high cholesterol, diabetes, and underweight or overweight/obesity. All increase the likelihood of heart ailments down the road.

Risk Factors 98

Risk Factors Blood Pressure Cholesterol Obesity 98

CardiacWire

JANUARY 22, 2025

On the clinical side, these outcomes can help physicians make more personalized patient treatment decisions, as the researchers pointed out people without diabetes and obesity likely wouldn’t experience many of these benefits. The post The Potential Risks of GLP-1s appeared first on Cardiac Wire.

Obesity 59

Obesity Cardiac Arrest Dementia Outcomes 59

Med Page Today

DECEMBER 19, 2024

(MedPage Today) -- The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 days to wrap up production and.

Obesity 111

Obesity Diabetes 111

Cardiovascular Diabetology

JUNE 28, 2024

The atherogenic index of plasma (AIP) is closely associated with the onset of diabetes, with obesity being a significant risk factor for type 2 diabetes mellitus (T2DM). However, the association between the AI.

Obesity 52

Obesity Diabetes Risk Factors Research 52

Cardiovascular Diabetology

NOVEMBER 14, 2024

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. GLP-1RA therapy has sho.

Obesity 107

Obesity Diabetes 107

The British Journal of Cardiology

OCTOBER 8, 2024

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.

Obesity 40

Obesity Diabetes Kidney Disease Heart Failure 40

Med Page Today

JANUARY 31, 2025

(MedPage Today) -- Just over half of patients with overweight or obesity discontinued their GLP-1 receptor agonist within 1 year, with rates even higher among the subset without type 2 diabetes, according to a retrospective cohort study.

Obesity 106

Obesity Diabetes 106

Science Daily - Heart Disease

JANUARY 17, 2025

These findings may inform efforts to prevent excessive weight gain early in life, a risk factor for adult obesity and related conditions, such as heart disease, high blood pressure and diabetes.

Blood Pressure 115

Blood Pressure Obesity Risk Factors Heart Disease 115

Med Page Today

JULY 8, 2024

(MedPage Today) -- In formulations indicated for type 2 diabetes, tirzepatide (Mounjaro) yielded more weight loss than semaglutide (Ozempic) in people with overweight or obesity, according to real-world data. In the first 3 months on treatment.

Obesity 104

Obesity Diabetes 104

American College of Cardiology

DECEMBER 23, 2024

The goal of the SURMOUNT-1 trial was to assess the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist versus placebo in overweight or obese adults without diabetes.

Obesity 56

Obesity Diabetes Article 56

CardiacWire

DECEMBER 6, 2023

The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.

Obesity 59

Obesity Diabetes 59